Andrea Vergara, Marco De Felice, Arturo Cesaro, Felice Gragnano, Ivana Pariggiano, Enrica Golia, Antonio De Pasquale, Ettore Blasi, Fabio Fimiani, Emanuele Monda, Giuseppe Limongelli, Paolo Calabrò
Immune checkpoint inhibitors (ICIs) are specific monoclonal antibodies directed against inhibitory targets of the immune system, mainly represented by programmed death-1 (PD1) ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), thus enabling an amplified T-cell-mediated immune response against cancer cells. These drugs have significantly improved prognosis in patients with advanced metastatic cancer (e.g., melanoma, non-small cell lung cancer, renal cell carcinoma). However, uncontrolled activation of anti-tumor T-cells could trigger an excessive immune response, possibly responsible for multi-organ damage, including, among others, lymphocytic myocarditis...
September 12, 2023: Angiology